ionis-stat3rx
Nucleic acidexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2012 (NCT01563302)
Timeline
Indications
Mechanism of action
- Signal transducer and activator of transcription 3ANTISENSE INHIBITOR
STAT3 antisense inhibitor
- STAT-3 mRNA 3'UTRANTISENSE INHIBITOR
STAT-3 mRNA 3'UTR antisense inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297739 ↗
Also known as
- ionis-stat3rx
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05986240 | Phase 1 | Jan 31, 2024 | Flamingo Therapeutics NV, University of Texas at Houston, Yeshiva University |
| NCT05814666 | Phase 2 | May 30, 2023 | Flamingo Therapeutics NV |
| NCT03794544 | Phase 2 | Mar 8, 2019 | MedImmune |
| NCT03819465 | Phase 1 | Dec 27, 2018 | AstraZeneca, University of California, San Diego |
| NCT01563302 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2012 | AstraZeneca, Ionis Pharmaceuticals, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 1 | 2 | 2012 |
| Flamingo Therapeutics NV | For profit | 2 | 1 | 2 | 2023 |
| Ionis Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2012 |
| MedImmune | For profit | 1 | 1 | 1 | 2019 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Yeshiva University | Academic/Hospital | 1 | 1 | 1 | 2024 |
7 organizations
Page 1 / 1